Pharmaceutical Research 1992: Vol 9 Index

11 Pages·1992·2 MB·English

Pharmaceutical Research, Vol. 9, No. 12, 1992
Author Index to Volume 9 (1992)
Abra, R. M., 220 Brewster, M., 743 Collins, L. R., 260 Elias, P., 1043
Abraham, P., 1474 Brinkley, M. A., 357 Colthorpe, P., 759 Elta, G., 901
Abraham, W., 1410 Brondsted, H., 1540 Connolly, M., 601 Endo, K., 908
Adjei, A., 244 Brooks, S., 939 Conradi, R. A., 435 Engineer, F., 1668
Ahrenstedt, O., 1243 Brophy, L., 1177 Constancis, A., 1563 English, J., 1436
Aird, S., 1231 Brouwer, K. L., 350 Cook, C., 588
Akers, W., 1145 Brunson, E. L., 255 Cordes, G., 575 Faber, E., 1442
Al-Rawithi, S., 115 Bryant, W., 570 Corvari, V., 1525 Farr, S., 759, 1137
Alcorn, L., 888 Buchmann, M., 788 Cossum, P. A., 419 Fawcett, V., 1428
Alfor. J., 1295 Bucks, D., 1164 Couch, R., 939 Ferguson, E., 1410
Alkan-Onyuksel, H., 1556 Bun, H., 1365 Couvreur, P., 441, 1534 Ferraiolo, B., 419
Alvarez, F., 1465 Bundgaard, H., 492 Crommelin, D., 266, 945 Ferro, L., 888
Amicabile, C., 1534 Bunel, C., 1563 Cyr, T., 1224
Fielding, R. M., 215
Amidon, G., 670, 856, 969, 1659 Burgess, D. J., 410
Findon, G., 1252
Amin, R., 1629 Burke, G. M., 126 D’ Emanuele, A., 215, 312, 1275 Firestone, B. A., 76
Ammon, H. L., 365 Burton, P. S., 435, 1103 Dahl, T. C., 398 Fischer, W., 575
Andersen, J., 817 Buur, A., 1290 Dalby, R., 636 Fix, J. A., 191
Anderson, G., 1622 Daly, P., 1436 Fleishaker, J., 457
AAAAAAAAAAAAAuprsunnuuuuywlipo,dnndrglatse, ge,rosez,t lss e,bn Juo,,te u.bY,r ,RJ ,sra.e. . He,gc,n,JL8. neh. .a2S,B,,,re,.612. 1, , ,20r,5 7 1 57 ,1171J6 6R 65.1261 4.L6 ,38 0,8.4 P6 7 , .201 ,5,3 4 011865 01,28 55 0 71 587 CCCCCCCCCCCCCaaaaaaaaaahhairrrnmniraanmlgrvaeocnmmlniomafé,la,blaolja,a l,g llnna ,cx ,nio,l ,NEkesG,, .. E.,s, R ,,F.,. ,J ., D,.T , P, ..6J 16. ,,.L44,18W3, .731 613 1.,34 0965 6 6157 421 43 4 501G37 9. 01, 255 dddDDddDDDDDDeeeeeaaaaaeee vvssnymLiihah,iRSMBVusei,o ucrmoec,,s iifhiee aJ ,ter,der. ,Aes,t ,leSP.r, ,i..,,, N , sM 1 . AP.,1,EB..9P,60 R..A,,9. 53,,. . 34 G 1 ,C11.518 A.15,4430.,70 5 7L 8, 8216 8 ,4 52 36 56 1521 FFFFFFFFFFFFFlloouurrrrrrrelryorryaaaaiitse,nnnbbnnesztl nzzeekcdh,,i,,,ss,o emW c ,, er.ah ,KuD,G,nTMP ..r . .,..AR,,,,,, ,.. D C 1, ..5 893M1,1 22E2M686 .151.96.353J,4 ,488 .,, 4 5 29, 8463 421111914690 2 72
Chang, C.-j., 582, 690 Desjardins, R., 826
Bae, Y. H., 283 Chappey, O., 1375 Devissaguet, J., 1534 Gabr, K., 960
Bai, J., 969 Charman, S. A., 87, 1219 Dick, 1., 884 Galante, L. J., 357
Bakhshaee, M., 654 Charman, W. N., 87, 1219 Dighe, S., 588 Gallo, J. M., 224, 390
Baldwin, J. R., 101 Chaturvedi, P. R., 595 Dobrinska, M., 1629 Ganguly, N., 1347
Baldwin-Ferron, A., 1386 Chavany, C., 441 Doelling, M., 1487, 1493 Garcia-Carbonell, C., 1587
Banfield, C., 469, 1284 Chellquist, E., 1341 Domb, A., 1279 Garcia-Carbonell, M., 1306
Bantle, S., 52 Chen Wang, Y.-M., 169 Dorantes, A., 677 Garland, W., 1099
Baron, C., 1654 Chen, A., 1480 Douglas, F. L., 236 Garrison M., 920
Baron, D., 1024 Chen, C.-C., 817 Douglas, R., 1502 Gaspar, R., 782
Barr, W., 826 Chem, M.-L., 1380 Down, G., 521 Geiger, J.-M., 1365
Bauer, L., 586 Chen, S. A., 419 Downing, D., 1410 Ghosh, M., 1048, 1173
Bechard, S., 521 Cheng, C.-C., 739 Dowty, M., 1113 Gipps, E., 1330
Beglinger, C., 52 Cheng, H., 339, 1629 Dressman, J., 901 Gleason, D., 578
Behl, C., 1107 Cheong, L., 1510 Drewe, J., 52 Glover, D., 1029
Belonio, B., 1024 Chesa-Jiménez, J., 1587 Drewniak-Deyrup, M., 372 Goldberg, A., 1659
Benet, L. Z., 187, 303, 826, 1460 Chien, D.-S., 769 Druzgala, P., 372 Golomb, G., 143, 1018
Berardi, R., 901 Chien, J. Y., 469 Driibbisch, V., 1644 Gonda, I., 1330
Berg, M. J., 126 Cho, P., 450 Duddu, S., 1083 Gonnella, N., 1035
Beuvery, E. C., 266, 945 Cho, S., 955 Dukes, G., 1190 Gonzalez, M., 1284
Bezooijen, C., 1456 Choi, H.-K., 963 Dunkle, J., 578 Good, W., 1035
Bhargava, K., 776 Choi, H.-S., 582, 690 Durand, A., 1365 Gorman, W., 1341
Bhat, M., 1029 Choi, R., 1451 Dutko, F. J., 87 Gossard, D., 683
Bhatt, R., 585 Choudhury, S., 1673 Dwivedi, C., 1668 Grandgeorge, M., 643
Bialer, M., 1058 Chu, J., 1659 Dwyer, K. A., 419 Granero, L., 1306, 1587
Boddé, H. E., 70 Chun, A., 244 Grant, D., 1083
Bodor, N., 372, 743, 1275 Chun, C., 1521 Ebling, W., 800 Grass, G., 1580
Bommannan, D., 559, 1043 Clair, J., 1664 Egbaria, K., 629 Gray, T., 901
Bouwstra, J., 70, 547 Clarke, F., 1035 Egermann, H., 385 Green, B., 945
Brange, J., 715, 727 Cleary, R. W., 255 Eitan, Y., 1018 Green, D. W., 58
Brazzell, R., 469 Coffin, M. D., 200 Ekblom, M., 155 Griffin, M., 888
Brennan, J., 654 Cohen, S., 37 El-Sharkawy, S., 623 Grove, J., 1563
Breuer, E., 143 Collins, J., 826 El-Yazigi, A., 115, 812 Guchelaar, H.-J., 808
0724-874 1/92/1200-1678$06.50/0 © 1992 Plenum Publishing Corporation
Pharmaceutical Research, Vol. 9, No. 12, 1992
Author Index to Volume 9 (1992)
Abra, R. M., 220 Brewster, M., 743 Collins, L. R., 260 Elias, P., 1043
Abraham, P., 1474 Brinkley, M. A., 357 Colthorpe, P., 759 Elta, G., 901
Abraham, W., 1410 Brondsted, H., 1540 Connolly, M., 601 Endo, K., 908
Adjei, A., 244 Brooks, S., 939 Conradi, R. A., 435 Engineer, F., 1668
Ahrenstedt, O., 1243 Brophy, L., 1177 Constancis, A., 1563 English, J., 1436
Aird, S., 1231 Brouwer, K. L., 350 Cook, C., 588
Akers, W., 1145 Brunson, E. L., 255 Cordes, G., 575 Faber, E., 1442
Al-Rawithi, S., 115 Bryant, W., 570 Corvari, V., 1525 Farr, S., 759, 1137
Alcorn, L., 888 Buchmann, M., 788 Cossum, P. A., 419 Fawcett, V., 1428
Alfor. J., 1295 Bucks, D., 1164 Couch, R., 939 Ferguson, E., 1410
Alkan-Onyuksel, H., 1556 Bun, H., 1365 Couvreur, P., 441, 1534 Ferraiolo, B., 419
Alvarez, F., 1465 Bundgaard, H., 492 Crommelin, D., 266, 945 Ferro, L., 888
Amicabile, C., 1534 Bunel, C., 1563 Cyr, T., 1224
Fielding, R. M., 215
Amidon, G., 670, 856, 969, 1659 Burgess, D. J., 410
Findon, G., 1252
Amin, R., 1629 Burke, G. M., 126 D’ Emanuele, A., 215, 312, 1275 Firestone, B. A., 76
Ammon, H. L., 365 Burton, P. S., 435, 1103 Dahl, T. C., 398 Fischer, W., 575
Andersen, J., 817 Buur, A., 1290 Dalby, R., 636 Fix, J. A., 191
Anderson, G., 1622 Daly, P., 1436 Fleishaker, J., 457
AAAAAAAAAAAAAuprsunnuuuuywlipo,dnndrglatse, ge,rosez,t lss e,bn Juo,,te u.bY,r ,RJ ,sra.e. . He,gc,n,JL8. neh. .a2S,B,,,re,.612. 1, , ,20r,5 7 1 57 ,1171J6 6R 65.1261 4.L6 ,38 0,8.4 P6 7 , .201 ,5,3 4 011865 01,28 55 0 71 587 CCCCCCCCCCCCCaaaaaaaaaahhairrrnmniraanmlgrvaeocnmmlniomafé,la,blaolja,a l,g llnna ,cx ,nio,l ,NEkesG,, .. E.,s, R ,,F.,. ,J ., D,.T , P, ..6J 16. ,,.L44,18W3, .731 613 1.,34 0965 6 6157 421 43 4 501G37 9. 01, 255 dddDDddDDDDDDeeeeeaaaaaeee vvssnymLiihah,iRSMBVusei,o ucrmoec,,s iifhiee aJ ,ter,der. ,Aes,t ,leSP.r, ,i..,,, N , sM 1 . AP.,1,EB..9P,60 R..A,,9. 53,,. . 34 G 1 ,C11.518 A.15,4430.,70 5 7L 8, 8216 8 ,4 52 36 56 1521 FFFFFFFFFFFFFlloouurrrrrrrelryorryaaaaiitse,nnnbbnnesztl nzzeekcdh,,i,,,ss,o emW c ,, er.ah ,KuD,G,nTMP ..r . .,..AR,,,,,, ,.. D C 1, ..5 893M1,1 22E2M686 .151.96.353J,4 ,488 .,, 4 5 29, 8463 421111914690 2 72
Chang, C.-j., 582, 690 Desjardins, R., 826
Bae, Y. H., 283 Chappey, O., 1375 Devissaguet, J., 1534 Gabr, K., 960
Bai, J., 969 Charman, S. A., 87, 1219 Dick, 1., 884 Galante, L. J., 357
Bakhshaee, M., 654 Charman, W. N., 87, 1219 Dighe, S., 588 Gallo, J. M., 224, 390
Baldwin, J. R., 101 Chaturvedi, P. R., 595 Dobrinska, M., 1629 Ganguly, N., 1347
Baldwin-Ferron, A., 1386 Chavany, C., 441 Doelling, M., 1487, 1493 Garcia-Carbonell, C., 1587
Banfield, C., 469, 1284 Chellquist, E., 1341 Domb, A., 1279 Garcia-Carbonell, M., 1306
Bantle, S., 52 Chen Wang, Y.-M., 169 Dorantes, A., 677 Garland, W., 1099
Baron, C., 1654 Chen, A., 1480 Douglas, F. L., 236 Garrison M., 920
Baron, D., 1024 Chen, C.-C., 817 Douglas, R., 1502 Gaspar, R., 782
Barr, W., 826 Chem, M.-L., 1380 Down, G., 521 Geiger, J.-M., 1365
Bauer, L., 586 Chen, S. A., 419 Downing, D., 1410 Ghosh, M., 1048, 1173
Bechard, S., 521 Cheng, C.-C., 739 Dowty, M., 1113 Gipps, E., 1330
Beglinger, C., 52 Cheng, H., 339, 1629 Dressman, J., 901 Gleason, D., 578
Behl, C., 1107 Cheong, L., 1510 Drewe, J., 52 Glover, D., 1029
Belonio, B., 1024 Chesa-Jiménez, J., 1587 Drewniak-Deyrup, M., 372 Goldberg, A., 1659
Benet, L. Z., 187, 303, 826, 1460 Chien, D.-S., 769 Druzgala, P., 372 Golomb, G., 143, 1018
Berardi, R., 901 Chien, J. Y., 469 Driibbisch, V., 1644 Gonda, I., 1330
Berg, M. J., 126 Cho, P., 450 Duddu, S., 1083 Gonnella, N., 1035
Beuvery, E. C., 266, 945 Cho, S., 955 Dukes, G., 1190 Gonzalez, M., 1284
Bezooijen, C., 1456 Choi, H.-K., 963 Dunkle, J., 578 Good, W., 1035
Bhargava, K., 776 Choi, H.-S., 582, 690 Durand, A., 1365 Gorman, W., 1341
Bhat, M., 1029 Choi, R., 1451 Dutko, F. J., 87 Gossard, D., 683
Bhatt, R., 585 Choudhury, S., 1673 Dwivedi, C., 1668 Grandgeorge, M., 643
Bialer, M., 1058 Chu, J., 1659 Dwyer, K. A., 419 Granero, L., 1306, 1587
Boddé, H. E., 70 Chun, A., 244 Grant, D., 1083
Bodor, N., 372, 743, 1275 Chun, C., 1521 Ebling, W., 800 Grass, G., 1580
Bommannan, D., 559, 1043 Clair, J., 1664 Egbaria, K., 629 Gray, T., 901
Bouwstra, J., 70, 547 Clarke, F., 1035 Egermann, H., 385 Green, B., 945
Brange, J., 715, 727 Cleary, R. W., 255 Eitan, Y., 1018 Green, D. W., 58
Brazzell, R., 469 Coffin, M. D., 200 Ekblom, M., 155 Griffin, M., 888
Brennan, J., 654 Cohen, S., 37 El-Sharkawy, S., 623 Grove, J., 1563
Breuer, E., 143 Collins, J., 826 El-Yazigi, A., 115, 812 Guchelaar, H.-J., 808
0724-874 1/92/1200-1678$06.50/0 © 1992 Plenum Publishing Corporation
Author Index
Guentert, T., 1299 Inman, A. O., 211 Kuo, B.-S., 119 Mamiya, M., 474, 1607
Guillory, J., 1640 Irons, B., 1113 Kurihara-Bergstrom, T., 1035 Manalo, J., 1518
Gupta, B., 1132 Ismail, 1., 817 Kwok, K. K., 410 Manning, M., 870
Gupta, P., 1502 Itoh, T., 1168 Kwon, Y., 1474 Marcek, J. W., 182
Gupta, S., 694 Marple, V., 1123
Gustafsson, L., 800 Jain, S., 990 Martin, F. J., 260
Guy, R., 187, 303, 559, 663, 1043 Jain, U., 792 Lacasse, Y., 683 Martin, J., 945
Jamoulle, J.-C., 82 Laganiere, S., 683 Martonen, T., 1634
Habon, I., 575 Jarowski, C., 1351 Lalan, P., 1386 Maruyama, T., 845
Lameh, J., 1644
Hadad, S., 1058 Jarvi, E., 1612 Masegi, M., 161
Hadgraft, J., 1137 Jarvis, D., 1668 Lampkin, T., 1190 Maskiewics, R., 860
Langer, R., 37, 1279
Haj-Yehia, A., 1058 Jay, M., 149, 1410 Mason, W., 929
Hak, L., 1190 Jekot, J. J., 260 Langkjoer, L., 715 Matsuda, Y., 307, 1673
Hall, I., 1324 Jenke, D., 1654 Larsen, C., 915 Matsuoka, Y., 1227
Hammerlund-Udenaes, M., 155 Jensen, B., 915 Larsen, F., 915 Matsushita, T., 697
Larson, T., 920
Han, Y.-H., 1190 Jewell, R., 1284 Maurin, M. B., 570, 1518
Hanano, M., 40, 271, 474, 1152, Jezyk, N., 1580 Lau, D. T., 187, 303, Mayer, P., 469
1394, 1607 Jiskoot, W., 266, 945 Lau, H., 901 Mayers, C., 1654
Harapat, S., 800 Johannes, |., 76 Laugier, J.-P., 1365 Mazer, N., 792
Lawrence, R., 1224
Harashima, H., 474, 1607 Johnson, J., 1145 Mazzo, D. J.,
Hardy, J., 1436 Johnson, M., 966 Layloff, T., 588 McBee, J., 687
Harrold, M., 1370 Johnston, T. P., 419 LeCluyse, E. L., 191, : McDowall, R., 588
Harter, J., 826 Jolicoeur, L., 963 LeDoan, T., 441 McGee, J. P., 464
Hashida, M., 161, 908 Jones, A. B., 255 Lee, D., 1575 McGilveray, I., 588, 683
Hassan, E. E., 390 Jones, D., 1487 Lee, H., 955 McGinity, J. W., 26, 200
Lee, K., 1521
Hatono, T., 161 Junginger, H., 70, 547 McNeil, S., 1422
Hauck, R-S., 850 Jurgens, T., 623 Lee, M.-H., 1599 Mehta, M., 224
Havelund, S., 715, 727 Jusko, W., 1096 Lee. P., 10, 195, 792, 979, 1268 Mehta, R., 1502
Hayakawa, E., 535, 769 Lee, Mehta, S., 1083
Hayashi, M., 648 Kakutani, T., 908 Lee, Meijer, D., 1442
HHHieelidizageyrra,e, n ,W .MR,.. , A1.11,92 04 32 28 KKKaaalnmoainini,sa k,i Y,. ,D .J,4. 0 ,9J 9.,01 339742 LLLLeeeeehgh,rem ,na dnrC,e. ,- MP..J,,. -Y17.10,4, 5 514273 5 MMMeeellletetznhedirrl,e, s,NS ..,, J.,21 32601 31,6 4 1256
HHHHHHHHHHHHHieéiiiiiieiiolklgldgncnr,ml1agoauezkg, mm4le,lcn, e,0ea,rC gh ey 2Jl sn.oi,,. s,N,Rn,,, P A . t. . ,., e,C2A A1 .iRW0.S.2,.H.n.,6 711D ,,. , ,859. ,R 741 ,.1 ,640 1,67 21 82K 93 6175.3244,1 5 0, 39 3 J50 3. 90,7 39 5,8 1107, KKKKKKKKKKKKKKaaaaaiieeaeeeerltttentsrlatmasrzzotsknlrarki,,,,ne,eanlyg e el ,iw,earnr, aLyBIYm,iE ,..y.,.. aDn,, ,M,, ,T. g, . .C,,1 ,J,. A16 196. ,.3I907,3.H1 2 7 2894U4,6.1, 486. 15S7, 8 ,24.15 1, ,6 41 1 4 3721738214 7870 8 2,4 497, 1083 LLLLLLLLLLLLLLeieeeiiiieeiii,vnnnnndwonvvm i,,,,,gip,yyn, Yas o.,e .t,l CJrTFS,eM. ..d..nM ,G.,R---,.a .,.RTCH8H, s,, ....6. 1, D ,,,4,C16. . 18C2,12,4.28 63641H 3,36 23 53. 8 3 29,70169 0 201 01 115 2 43 MMMMMMMMMMMMMMeiiiieeieieiiilllkstztcrsydnlllehcreohiehoeeelhaai,rsarrrrnle,l, a,k,,,,,,l i , o l ,B -,A .JTMNJL K.M.,G....D.,,.i ,.,,M,. ,J, ,v . , . 1 2e6 ,,3104 21r 5212994111386s835956 092 ,875i 25146 3 09d 230 g 5 8e6,, 8E6.4,, 11170073 ,
Ho, N. F., 435 Kim, A., 504 Lindenbaum, S., 480, 1203 1048, 1157, 1173, 1184, 1262,
HHHHHHHHHHHHHHHHHoooouooouoouuuuwwrfcffonsrkuaucmaa1aftswhvffgnaghb3nno,,aiemmhagh6nemggr it2raaaa,tsra,d,,nz,nnur ooMsS,n ,, ,,sdn.n. t , Y ,,,1 ,CKoJ. C5 . A ..MA,nS0AM., ..-. .Je7. .,GP,GMD,,.C,,,., .1 .. .1 .D , , 2,,1,,7. H73 58 0 6, 1.13517743A, 0,52 5025082 . 19 1167 ,0375,81812 8461 6 3, 9 3 0 16 116202 16 12,99 57 50, KKKKKKKKKKKKKKKKKKiiiiiiinnnoooooooosmmemtnmuuvddkuceps,,v,agtuata,apnhee e mhhlrs ,p,liacl,u,oa,o a gkeCSD, W rr,nrb,..k. .anY K,i- a T-,C,K..,,J s.uC.W A., ,. R,,G.,e.., , . L. , ,5r J ,,DS4.4 . 4 5,7..,1,1M71125, ,5M44401 2.1 0 80. ,182 11 2,, M3137252 , .3 7A044 1,8.2 00393, ,76 54 19,59, 0,931 4691,4 12 10364 98514 15 68 LLLLLLLLLLLLLLLLLiiiiioououuoouuuuuuuupfd,,,dvnnn,nd,,,p th edtegdd osierre,qeDHMls,C,,irDFP v.n..d.o . .. n,i --,,,,n-J-g sy H . yS C,FRP,t,...... .. 71 R, ,,,,T,B,,09. 7 . . TA32 E3,,..659 .1 511T,78A,7 3,6 .51 39. 830 71,7994,,2 71 2,559 16 41 9 2 315352,158 5 45 217, 57 16 2 17559 2 MMMMMMMMMMMMMMMMMoiooooooouooouuooftryhlénjdklrhsnr1ifiolrtsalhdkh3atdlatesievi1,ee,enlgtaerh,4imrer ro,,n,o,i najr,r,, i ,mtnio i AN , K.n,e-.ai BR1P.,,, RMNnr..G,6., T . .,,i,.,7y S. , ,,1Ev. 2,, 1 .6 ,,H9i 4752 , 9.J8.,e 10P876 9871, .930r558041 0 ,1P 82 e17 579 .6 90, 2,974 79 3501 90 0N 1. , 211
Hwang, S., 694 Kramer, P., 1064 Mumper, R. J., 149
Kreuter, J., 541, 1534 Ma, J., 1029 Munro, C., 1199
Ichihashi, T., 1617 Krisnamoorthy, R., 1157, 1314 Ma, P., 1518 Muranishi, S., 1195
Iga, K., 658 Kroon, D., 1386 Ma, S. X., 735 Miiller, B., 554
Iga, T., 474, 1152, 1607 Krueger, G. G., 45 Macheras, P. E., 94, 1568 M@rk, N., 492
Ilium, L., 878 Krumphuber, A., 385 Maibach, H., 1164, 1365
Inagaki, K., 769 Kumar, N., 365 Maincent, P., 1534 Nakar, D., 276
Indelicato, J. M., 250 Kumar, V., 990 Malanga, C., 1029 Nakazora, S., 908
1680 Author Index
Nam-Tran, H., 788 Puisieux, F., 441 Sandouk, P., 1375 Stauffer, P., 559
Nara, E., 908 Punjabi, M. A., 419 Sarkar, M. A., | Stavchansky, S., 677
Nara, E., 161 Sawada, T., 648 Stebler, T., 1299
Narang, P. K., 101 Qi, H., 1370 Sawada, Y., 271, 474, 1152, 1607 Steel, V., 1177
Nash, R., 1487, 1493 Qian, M., 224 Sawchuk, R. J., 228, 332 Steffan, A-M., 541
Nashed, N., 480 Qiu, Y., 1640 Schaefer, H., 1107 Steffan, B., 575
Nassiri, M., 963 Quan, H., 1629 Schafer, V., 541 Stein, E., 1629
Nau, H., 850 Qureshi, S., 683 Schentag, J., 826 Stella, V. J., 58, 378, 497, 617,
Needham, T., 888, 1024 Scherrmann, J.-M., 643, 1375 1076, 1209
Neefjes, J., 1442 Schilling, R., 1003 Stevens, H., 654
Radebaugh, G., 1083
Nesbitt, R. U., 595 Schlossman, A., 143 Stijnen, A., 1456
Radwanski, E., 450
Newman, M. S., 260 Schmidt, E.-W., 291 Storm, G., 260
Radzik, D., 933
Neyfakh, A., 700 Schmidt, R., 1024 Straughn, A., 1612
Raghavan, K., 626, 743
Nickerson, D., 1515 Schnaare, R. L., 406 Strohbeck, C., 365
Rahman, M., 1474
Niven, R., 515 Schoenhard, G., 888, 1024 Su, M.-H.,
Raines, D., 812
Noach, A., 547 Schottelius, D., 126 Sue, I.-1., ;
Rakhit, A., 236
Noctor, T., 480 Schreier, H., 515 Sugimoto,
Rana, R. K., 33
Noonan, P., 1284 Schulteis, B., 870 Sugita, E. T.,
Ranadive, S., 1480
Niirnberg, E., 1336 Schultz, R., 1123 Sugiyama, Y., 40, 271, 474,
Rao, G., 1575
Scott, R., 884 1152, 1394, 1607
Reigner, B., 1053
Seaman, W. J., 182 Sun, J., 1451
Ogawa, T., 648 Rescigno, A., 17, 925 Seibert, W., 1525 Sundberg, D., 244
Ogawa, Y., 658 Ressing, M. E., 266 Serajuddin, A., 1480 Surber, C., 1365
Ohnuma, N., 40, 1394 Reuning, R. H., 169 Seybert, D., 1370 Suryanarayanan, R., 993
Okamoto, Y., 138 Reynolds, D., 1324 Shafer, S., 800 Suttle, A. B., 350
Okita, J., 1648 Richardson, J., 878 Shah, V., 45, 588, 826, 1107, Sutton, S. C., 191, 316
Okita, R., 1648 Richman, J., 817 1612 Suzuki, N., 1227
Okudaira, K., 1152 Rider, J. N., 255 Shanker, R., 480 Sveinsson, S., 1359
OOlkdufyilaemda, , N.H,. , 1059599 , 1043 RRiidgeord,, PJ.. , H.1,0 532 55 SShhaaor,m a,Z ., Y.8,6 4,1 64141 57, 1184, 1262 SSwwaagrlberri,c k,A . J.R,. , 1524264, 1550
Olerud, J., 1145 Riley, C., 1256 Shaw, D., 687 Sweany, A., 1629
Olesen, H., 915 Riviera, J. E., 211 Shaw, P. N., 464 Szoka, Jr., F., 260, 504, 1235
Oliyai, R., 617 Robertson, J., 1410 Sheiner, L., 826 Szpunar, G., 901
Olofsson, I.-M., 1592 Robinson, J., 1113 Shetty, B., 1677
Omelczuk, M. O., 26 Rodman, !., 826 Shields, L., 1428
Oosting, R., 1442 Rodvold, K., 966 Shier, W., 1677 Tabata, S., 529
Opperdoes, F., 782 Roe, J., 835 Shim, C.-K., 1599 Tabibi, E., 1347
Ormrod, D., 1252 Rogers, D., 1629 Shimura, T., 529 Tachibana, K., 952
Osaki, E., 800 Rogers, J., 759 Shipman, C., 963 Tada, T., 138
Otagiri, M., 845 Rogers, N., 626 Shroot, B., 82 Takada, K., 1195
Oth, M., 298 Rogge, M. C., 87 Shultz, R., 860 Takagishi, Y., 1617
Otsuka, M., 307, 1673 Rohera, B., 1351 Sideris, E., 1568 Takakuwa, S., 529
Ouchi, H., 648 Rohlifs, S., 1668 Siegel, R. A., 76 Talsma, H., 266
Rojanasakul, Y., 1029
Silbering, S. B., 595 Tamada, J., 1279
Roland, M., 782
Silver, B. S., 45 Tan, X., 1203
Paalzow, L., 1243 Rolland, A., 82 Silvestri, S., 1347 Tang, J.-p., 236
Pal, M., 1132 Rominger, K. L., 291 Simlot, R., 1324 Tanzer, J., 1064
Palsmeier, R., 933 Rosen, J., 450 Sims, S., 1402 Tate, A., 1629
Parish, R. C., 390 Rossi, D. T., 101 Sinko, P. J., 320 Taylor, G., 759
Park, G.-B., 326, 1262 Roth, M., 419 Sintov, A., 276 te Booy, M. P., 109
Park, T. G., 37 Rotschafer, J., 920 Sisko, J., 1076, 1209 Temple, R., 826
Parpaleeva-Kiihn, V., 1336 Roufos, I., 735 Siverly, J., 1546, 1550 Terao, T., 607
Pasini, C. E., 250 Roy, S., 1132 Sjoberg, P., 155, 1592 Teraoka, R., 307, 1673
Pasternacki-Surian, J. M., 406 Royer, C., 541 Skelley, J., 45, 588, 826 Terasaki, T., 529
Patel, S., 753 Rozier, A., 1563 Slade, R., 1465 Thermes, F., 1563
Peck, C., 826 Rubas, W., 1580 Slattery, J., 469 Thomas, J., 894
Pelekoudas, K., 901 Rubinstein, A., 276 Smith, C., 870 Thomas, N., 879
Pelsor, F., 1612 Ruelle, P., 788 Smith, F. W., 33 Thouvenot, P., 1534
Peris-Ribera, J.-E., 1306, 1587 Ruggirello, D., 1284 Smith, I., 75 Timmermans, J., 298
Pershing, L. K., 45 Rullo, G., 939 Smith, R., 1487 Ting, T.-Y., 1330
Philip, M., 1644 Rummelt, A., 52 Smith, S., 372 Toguchi, H., 658
Philips, B. A., 101 Rush, B., 1103 Soine, W. H., 613 Tomita, M., 648
Piraino, A., 1451 Ruwart, M., 1103 Son, K., 1556 Tomlinson, R., 1145
Pittman, K., 588 Riibsamen-Waigmann, H., 541 Song, H., 1521 Torres-Molina, F., 1306, 1587
Pla-Delfina, J., 1587 Ryde, M., 1243 Southard, M. Z., 58, 694 Toscano, J., 920
Plazonnet, B., 1563 Rytting, H., 1168 Sparrow, R., 654, 1436 Tozer, T., 1053
Ploegh, H., 1442 Spector, S., 588 Trattner, T., 860
Pollack, G. M., 350 Saadeh, H.. 143 Spireas, S., 1351 Triggle, D., 1474
Poole, J. C., 119 Sabouraud, A., 643 Sriburi, A., 1370 Tréster, S., 541
Poon, W., 1123 Sadée, W., 1644 Sridhar, R., 178 Tsantili-Kakoulidou, A., 1321
Potts, R., 663, 1422 Safi, H., 613 Srinivasa, V., 1402 Tse, F., 1515
Pouton, C. W., 87 Saheki, A., 529 Stalker, D., 1410 Tsuji, A., 529
Pretzer, D., 870 Salmon, J., 1231 Staniforth, J. N., 215, 312 Tukker, J., 894
Préat, V., 782 Sanathanan, L., 826 Stanski, D., 800, 826 Turunen, T., 1168
Author Index
Uges, D., 808 Volund, A., 715 Wester, R., 1164 Xiong, H., 739
Uhl, J., 1177 von Briesen, H., 541 Westkaemper, R. B., 613
Urtizberea, M., 643 Vudathala, G., 759 Wientjes, G., 822, 1070 Yacobi, A., 588, 826
Wilding, I., 654, 1436 Yalkowsky, S., 753, 955
Wilkinson, K., 1103 Yamada, H., 1617
Vadino, W., 450 Wagner, J., 901 Williams, M., 1190 Yamada, S., 1227
Vairon, J.-P., 1563 Wainer, I., 480 Wilson, T. D., 87 Yamamichi, R , 845
Valsami, G., 1568 Wald, J., 1096 Winwood, D., 372 Yamamoto, A., 769
Valsami, N. V., 94 Walker, L. A., 255 Won, C. M., 131 Yamazaki, M., 474, 1152,
Van de Werken, G., 945 Walters-Thompson Wong, L., 1510 1607
Van Gelder, J. M., 143 Wang, L.-Y., 1029 Wong, O., 1324 Yasuda, T., 138
Van Berkel, T., 565 Wang, W., 769 Wong. S. L., 228, 332 Yokoyama, T., 697
van Ingen, C. W., 266 Wang, Y., 332 Wood, G., 1612 York, P., 1428
Vance-Bryan, K., 920 Wasinger, L., 1168 Woodle, M. C., 260 Yoshikawa, H., 1195
Van der Velde, D., 870 Watrous-Peltier, N Wright, E., 457 Yoshioka, S., 607
Vandlen, R., 419 Weaver, M., 1064 Wu, L.-S., 750 Yu, D., 1659
Veng-Pedersen, P., 126 Weaver, R. J., 182 Wu, W., 1275 Yuk, S., 955
Vickery, R., 570, 1518 Weiner, N., 1659 Wu-Pong, S., 1010
Vidmar, T., 1103 Weiss, T., 1010 Wurster, D. E., 126 Zentner, G., 1664
Vishwanthan, C. T., 224, 588, Weissinger, J., 826 Wyandt, C. M., 255 Ziegler, A., 554
826 West, D., 585 Wyatt, D., 759 Zour, E., 595
Pharmaceutical Research, Vol. 9, No. 12, 1992
Subject Index to Volume 9 (1992)
l-aminobenzotriazole, 1099 azone, cimetidine, 817
1-carba-1-dethiacephalosporin, solution stability, 250 azone, penetration enhancer, 303
1-deoxymannojirimycin, pharmacokinetics, 1442
1-phenylvinyl phosphate, kinetics, 378
B-cyclodextrin-anilinonaphthalenesulfonates, 1568
2-hydroxypropyl-B-cyclodextrin, 1673
bacterial monitoring, vials, 357
2’ ,3’-dideoxyinosine, nonlinear disposition, 1070
benzoyl peroxide, kinetics, 1341
2’ ,3'-dideoxyinosine, pharmacokinetics, 822, 1070
7H nuclear magnetic resonance, 1415 benzoyl peroxide, stability, 1341
betamethasone dipropionate, bioavailability, 45
4-(2-N,N-Di-n-propylaminoethyl)-5-hydroxyindole derivatives, 735
bilayer, floating unit, 298
5-aminosalicylic acid, calcium alginate beads, 1128
bile salt, acylcarnitine, mixed micelles, 1262
5-aminosalicylic acid, degradation, 933
bile sequestrants, 670
5-ester prodrugs, 1048
binding EGF, 40
5-fluorodeoxyuridine, oleoyl derivatives, 565
biodegradable microspheres, 1502
5-iodo-2'-deoxyuridine, enhanced delivery, 1173
bioequivalence index, 925
5-iodo-2'-deoxyuridine, metabolism, 1048
bioequivalence studies, 1380
5-lipoxygenase inhibitor, 1465
biomimetic polymers, 586
6-mercaptopurine, rectal administration, 697
biosensor, 835
1,2-diaminomethyl-cyclobutane-platinum(II) lactate, 808
bisacylphosphonates, 143
13-cis-retinoic acid, solid state stability, 1203
[(’H]tetracycline kinetics, 1018 bisphosphonates, 143
bisphosphonates, bone resorption, 1018
a-chymotrypsin, 864
bone infections, treatment, 993
a-cyclodextrin, NMR, 575
brush border membrane, EGF binding sites, 1394
a,-acid glycoprotein, 845
bupranolol, pharmacodynamics, 554
absorption rate, 1380
absorptive-mediated endocytosis, ACTH, 529 bupranolol, supersaturation, 554
acetophenone, 378
acetylator phenotype, 812 c-myc oligonucleotide uptake, 1010
acitetrin, HPLC, 1365 CACO-2 cell monolayers, 1290
acitetrin, pharmacokinetics, 1365 calcium alginate beads, 1128
activated charcoal, XPS, 126 cancer immunotherapy, 425
acyclovir permeation enhancement, 1262 capacitive sensor, 1525
acyclovir, controlled (trans)dermal delivery, 979 captopril, 1224
adinazolam mesylate tablets, pharmacokinetics, 457 captopril, pulsatile release, 654
ADR-529, pharmacokinetics, 101 captopril, systemic absorption, 654
adrenocorticotropic hormone, 529 carbamazepine, bioavailability, 1612
aerosol, impinger, 1123 carbamazepine, pharmacokinetics, 1612
aerosol, formulation, 636 carbopol gel, 1659
aerosol, insulin, 764 cardiac glycosides, 1152
aerosols, 515 cardioprotectant (ADR-529), HPLC, 101
aerosols, 1634 carotenoids, 700
age percutaneous absorption, 884 cefoxitin, bioavailability, 191
air-gap electrode, 485 cefoxitin, colon, 191
albumin microspheres, 629 cefuroxime axetil, diastereomers, 687
alkylpyrazine odor modalities, 1321 celiprolol, 2D-NMR, 365
all-trans-retinoic acid, solid state stability, 1203 celiprolol, crytal structure, 365
amino acid side chains, 504 cellulose acetate, 1664
aminopeptidase inhibitors, 535 ceramides, 1415
amoxicillin, otitis media, 920 chemical dehydration, albumin emulsion, 776
amoxycilin, pharmacokinetics, 1587 chemoprevention, garlic, 1668
angiotensin-converting enzyme inhibitors, 1480 chemoreceptor, 835
angiotensin-converting enzyme (ACE) inhibitors, 969 chewing gum products, medicated, 255
anthracyclinones, 739 chlorinated hydrocarbons, captopril, 1224
Anti-AIDS agents, 703 chloroethylnitrosoureas, 743
antiepileptic, gabapentin, 595 chlorpheniramine maleate, extended-release formulations, 450
antipyrine pharmacokinetics, 1515 chlorpheniramine, absorption profile, 450
antipyrine, pharmacokinetics, 1587 CHO-K1 cells, 178
antisense, oligonucleotide, 1010 cholecystokinin-B, 1092
antiviral drug targeting, 541 cholesterol, bile salt, 792
antiviral eficacy, systemic, topical, 979 cholestyramine, bile salt, 670
aspirin hydrolysis, kinetics, 1673 CI-988, aqueous stability, 1092
aspirin, hydrolysis, 159 clinical pharmacokinetics, 966
asthma, new drugs, 585 colonic absorption, thymidine analogues, 326
autoxidation, ethyl icosapentate, 1673 colonic drug delivery, 1540
0724-874 1/92/1200-1682$06.50/0 © 1992 Plenum Publishing Corporation 1682
Subject Index
colonic drug delivery, indomethacin, 276 epithelial transport, 1029
computer-controlled drug delivery, 800 epitiostanol, 1617
controlled drug delivery system, 312 erodible polymers, 1279
copolymers, mucoadhesion, 1563 ethylicosapentate, 1673
corticosteroid metabolism, 1275 etorphine, transdermal delivery, 963
corticosteroids, topical, 45
crisnatol metabolite, 623 Fab, immunoreactivity, 643
curdian, drug delivery, 414
fenoterol, pharmacokinetic/dynamic correlation, 291
cyclic hexapeptide, degradation, 1314 fibrolase stability, 870
cyclic hexapeptide, kinetics, 1314
flow-through diffusion cell, 82
cyclic peptide, peptide bond cleavage, 617 fluid cushion device, 753
cyclodextrin (CD)-benzaldehyde complexes, 582
fluid-bed dryer, 1487, 1493
cyclodextrin/drug comlexation, 1568
fluorescein dyes, albumin microspheres, 629
cyclodextrin/weak electrolyte, complexation, 1671 flurbiprofen, 492
cyclodextrins, 94 flurbiprofen, absorption, 901
cyclodextrins, nasal absorption promotors, 1157 flurbiprofen, fasted state, 901
cyclosporin A, isomerization, 617
Fourier transform infrared spectroscopy, BSH, 1199
cyclosporin a, 1252 FR71021, powder X-ray diffraction, 138
freeze drying, monoclonal antibody, 266
degradation of proteins, 1386 freeze-drying, pharmaceuticals, 753
degradation, drugs, solid state, 939 furosemide, protein binding, 155
dermal diffusion, 1256
dially! sulfide, chemoprevention, 1668 gabapentin, stability studies, 595
diazepam, excretion in milk, 1299 gelatin gels, drug stability, 607
dicumarol, 845 gene therapy, 1235
diethyl phthalate, 1648 glutaraldehyde cross-linking, 10
differential scanning calorimetry, freeze dried sucrose, 109 glutathione S-transferase, 1460
dihydropyridine chemical delivery system, 743 glyceryl trinitrate, 1460
diltiazem, 1599 granulation monitoring, 1525
dinitrate metabolites, 1284 griseofulvin release, 759
diphenhydramine, HPLC, GC-MSD, 929
dipyridamole, 178 1-pyrromycinone derivative, 739
discontinuous GI absorption. pharmacokinetic model, 350 hapten, monoclonal antibody, 1375
disopyramide, protein binding, 155 hepatobiliary transport, phenol red, 908
dissolution testing system, 578 heteropolyanion, 570
dopaminergic agonism, 735 hexamethylene lauramide, 817
droperidol, pharmacokinetics, 694 human immunodeficiency virus (HIV), phagocytosis, 541
drug absorption, pharmacokinetics, 161 human immunodeficiency virus (HIV-1), drug development, 703
drug delivery device, electrically modulated, 215 human serum albumin, acetylation, 480
drug delivery systems, electric stimulus, 955 hydrochlorothiazide, fast release, 960
drug delivery, ion exchange, 1654 hydrochlorothiazide, nonreverting, 960
drug development, pharmacodynamics, 826 hydrocortisone, bioavailability, 1164
drug development, pharmacokinetics, 826 hydrocortisone, percutaneous absorption, 1164
drug dissolution, ionizable drugs, 58
hydrogel, colonic drug delivery, 1540
drug interaction, HIV, 224 hydrogels, loading, 283
drug monitoring, 812 hydrogels, release kinetics, 283
drug protein binding, 480 hydrogels, swelling, 283
drug release rate heat-induced, 658 hydrophilic creams, 1336
drug release, 1510 hydroxyurea, analysis, 115
drug release, film coated pellets, 398 hydroxyurea, hydrolysis, 115
drug release, optimization, 206 hypolipidemic agents, 1324
drug release, swelling controlled, 195, 1268
drug targeting, antiviral, 541
DuP 747, kappa agonist analgesic, 750 ibuprofen, 492
DuP 925, physicochemical properties, 570 iceberg formation, 159
ICRF-187 (ADR-529), hydrolysis, 1209
ICRF-187 [( + )-1,2-bis(3 ,4-dioxopiperazinyl!-1l-yl)propane], 1076
electroosmosis, 1402 IgG, immunoreactivity, 643
electrophoresis, 215 imide, ICRF-187 (ADR-529), 1076
electrospray mass spectrometry (ES-MS), 945 imirestat, pharmacokinetics, 469
electrotopological state index, 1321 imirestat, tissue binding, 469
emulsion filtration, 860 indomethacin, colonic delivery, 276
emulsion stability, 860 indomethacin-loaded microspheres, 1132
emulsions, renin inhibitor, 888 inestinal permeability, drug absorption, 1243
enkephalin metabolites, 990 infrared imaging/thermography, pharmaceuticals, 521
enkephalin, nasal absorption, 1362 infusion pumps, computer controlled, 800
enterohepatic circulation, 169 insulin dissociation, 864
enterohepatic recirculation of drugs, 1306 insulin preparation, 727
enzyme electrode, 485 insulin, chemical stability, 715, 727
enzyme technology, 835 insulin, conjunctival penetration, 769
ephedrine, enantiomers, 1083 insulin, hydrolic degradation, 715
ephedrine, thermadynamics, 1083 insulin, intravenous, 1003
epidermal growth factor (EGF), 40, 271 insulin, pharmacodynamics, 1003
epidermal growth factor, binding sites, 1394 insulin, phonphoresis, 952
1684 Subject Index
insulin, transdermal delivery, 952 microfluidization, 1347
insulin, vaginal absorption, 878 microspheres, poly(L-lactic acid), 149
interleukin-2, sustained delivery, 425 microwave dryer, 1487
interparticulate friction, 521 misoprostol, capsule, 298
intestinal drug and water absorption, 894 mitoxanthrone, cytotoxicity, 178
intestinal perfusion, 894 mixed micelles, 1184
intestinal perfusion,drug absorption, 1243 mixed-effects analysis of variance, 345
intestinal permeability, 1580 MK-927, kinetics, 339
intestinal tissue permeability, 316 MK-927, stereoselective binding, 339
intrasubject variance, 345 ML-1035, a metoclopramide analogue, HPLC, 119
intravenously injected substances, pain, 182 ML-1035, metabolites, 119
ion-selective electrodes, 94 mobile order, 788
ionizable drugs, mathematical model, 58 monoclonal antibody (MN12), lyophilization, 266
iontophoresis, 1402 monoclonal antibody, 1386
isoflurane anesthesia, 1515 monoclonal antibody, ES-MS, 945
monoclonal antibody, hapten, 1375
multidrug resistance, tumor cells, 700
jejunal drug absorption, 648
multiple emulsification, indomethacin, 1132
muscarinic agonist, 1474
ketoprofen, prodrugs, 915 muscarinic cholinergic HmI receptor, 1644
ketotrilostane, pharmacokinetics, 464 myo-inosito 1-phosphatase, inhibition, 1370
laurate hydroxylation, 1648 N(4-methylphenyl)diphenimide, 1324
Leishmania donovani, 782 N-desmethyladinazolam, pharmacodynamics, 457
leuprolide acetate, bioavailability, 244 N-methyl-1-deoxynojirimycin, 1442
leuprolide acetate, nasal, lung, delivery, 244 Na,K-ATPase, saturable binding, 1607
leuprolide, absorption enhancement, 1575 naphthoic acid derivative, 82
levothyroxine, degradation, 131 naproxen, enteric-coated tablets, 1436
levothyroxine, solid state, 131 nasal absorption, 1184
libenzapril, chronic hypertension, 236 nasal cytochrome P-450, |
lidocaine, iontophoresis, 211 nasal delivery, polyvinyl! alcohol, 1330
lipid metabolism, 1324 nasal metabolism, |
lipophilic drug, 87 nasal peptide delivery, 626
lipophilicity, ACE inhibitors, 1480 nicardipine, 1518
liposomal triamcinolone acetonide, 1359 nicotine TTS, transdermal pharmacokinetics, 1451
liposome, thermosensitive, 658 nicotine, transdermal, pharmacodynamics, 1451
liposomes, long circulating, 260 nifedipine, alcohol interaction, 683
liposomes, nebulization, 515 nifedipine, pharmacokinetics, 683
liposomes, pH-sensitive, 1235 nitration, methods and mechanism, 586
liquid crystalline phases, 1546, 1550 nitrofurantoin monohydrate, 307
lobaplatin D19466, 808 nitrofurantoin, anhydrate, dissolution kinetics, 307
local enhanced topical drug delivery, 1422 nitroglycerin, 1460
lonapalene, percutaneous absorption, 1145 nitroglycerin, cutaneous metabolism, 187, 303
lonapalene, psoriatic skin, 1145 nitroglycerin, transdermal, 1284
loracarbef, solution stability, 250 NMR methods, drug design, 966
lotprednol etabonate, 1275 nonsteroidal antiinflammatory drugs (NSAIDs), extended release,
lovastatin, plasma levels, 1629 206
lymphatic targeting, 1534 nordazepam, excretion in milk, 1299
lymphatic transfer, 1195
lyophilization of proteins, 33 octanol-water partition coefficient, 504
octreotide, 52
macrogolstearate 400, lamellar phase, 1336 ocular drug delivery, mucoadhesion, 1137
macromolecules, 1195 oleic acid, monoolein, emulsions, 1024
magnetic microspheres, oxantrazole, 390 oligonucleotides, 441
mathematical model, ionizable drugs, 58 osmotic pumps, 1664
matrix system, 1510 ouabain, binding to Na,K-ATPase, 474
mefloquine stereoisomers, HPLC, 1640 ouabain, kinetic modeling, 1607
mepirodipine, determination, 1227 ouabain, tissue binding, 474
mepitiostane, 1617 oxantrazole, magnetic microspheres, 390
mercaptoundecahydrododecaborate, quantitative analysis, 1199 oxidative decomposition, 5-aminosalicylic acid, 933
metered dose inhaler sprays, impinger, 1123
metered-dose inhalers, flammable propellants, 636 p-aminohippurate, 271
method equivalence, 601 p-chloro-m-xylenol (PCMX), pharmacokinetics, 677
methotrexate, 1295 pain, intravenously injected substances, 182
methotrexate, oleoy! derivatives, 565 palmitoyl L-cartinine, 191
micellar electrokinetic capillary chromatography, 1219 particle size, characterization, 856
micellar solubilization, 750 pentachlorophenol, toxicokinetics, 1053
microbial metabolism, crisnatol, 623 peptide analogues, intestinal absorption, 320
microdialysis perfusion, 1256 peptide bioavailability, 535
microdialysis, pharmacokinetics, 155 peptide drugs delivery, 260
microdialysis, theophylline, 1592 peptide drugs, conjunctival penetration, 769
microencapsulation, 410 peptide drugs, metabolism, 969
microencapsulation, griseofulvin, 759 peptide mapping, 1386
Subject Index
peptide transporter, 969 R( + )-and S( — )-2-n-propyl-4-pentynoic acid, 850
peptide, nasal absorption, 1362 radioligand binding, 1474
peptide, permeability, 435 radioreceptor assay, mepirodipine, 1227
peptide, transport, 435 ranitidine, site of absorption, 1190
peptides, absorption, 1103 receptor binding pocket, 1644
peptides, intestinal absorption, 320 receptor-mediated endocytosis, 1394
percutaneous absorption, 5-iodouracil, 1410 recombinant interleukin-2, 425
percutaneous absorption, 1546, 1550 rectal delivery, droperidol, 694
percutaneous absorption, age, 884 relaxin, pharmacokinetics, 419
perfluorocarbon, centrifugation, emulsification, stability, 406 renin inhibitor, nasal delivery, 1024
permeability, membrane, 1029 renin inhibitor, oral delivery, 888
permselectivity, membrane, 1029 reptile venom, 1231
pH-rate profile, ICRF-187, 1209 resorfin, 1099
phagocytosis, suppression, 1177
pharmaceutical gel formulation, 1659 salmon calcitonin, degradation, 1521
pharmacokinetic model, discontinuous GI absorption, 350 salts of p-aminosalicylic acid, 1428
pharmacokinetic studies, 588 samarium-153, 1436
pharmacokinetic/dynamic correlation, fenoterol, 291 self-emulsifying drug delivery systems, 87
pharmacokinetics experimental design, 169 shape analysis, 856
pharmacokinetics, amoxicillin, 920 shed snake skin, permeability, 1168
pharmacokinetics, compartmental and noncompartmental, 17 silicone elastomer dispersion, 398
pharmacokinetics, drug absorption, 161 simvastatin, plasma levels, 1629
pharmacokinetics, HIV, drugs, 224 site-directed mutagenesis, 1644
pharmacokinetics, human relaxin, 419 skin metabolism, 187
pharmacokinetics, ketoprofen, 915 skin penetration, 1215
pharmacokinetics, pulmonary delivered insulin, 764 skin permeability, 663
phenobarbital, chronic administration, 908 skin pharmacology and toxicology, 585
phenobarbital, metabolism, 1633 skin transport enhancement, 1035
phenobarbital, pharmacodynamics, 1295 sodium 5-(4-oxo-phenox y-4H-quinolizine-
phenobarbital, pharmacodynamics-pharmacokinetics, aging, 1456 3-carboxamide)-tetrazolate, 138
phenothiazine derivative, 845 sodium caprate, absorption enhancer, 648
phenylpropanolamine hydrochloride, 255 sodiumtaurodihydrofusidate, absorption enhancer, 52
phenytoin, protein binding, 155 solid state stability, drugs, 939
phosphate esters, 497 sonophoresis, 559
phosphinic acid dipeptide analogue, 626 sonophoresis, 1043
phosphomonoester prodrugs, 497 statistical power calculations, 601
pilocarpine derivatives, water soluble, 372 steady state volume, 17
pilocarpine, analysis, 1219 stereoselective enzymatic hydrolysis, 492
pilocarpine, pharmacokinetics, pharmacodynamics, 1064 sterility of the interior microcapsules, 410
pilocarpine, prodrugs, 372 submicron emulsions, 1347
plasmid DNA, 1235 sucrose, freeze dried, 109
plasticizers, 1648 surface free energy, microadhesion, 70
poisson distribution, random mixtures, 385 sustained-release, propranolol, 1507
poly (€-caprolactone), chemical stability, 200 Sweetana-Grass diffusion cells, 316
poly(D,L-lactide), chemical stability, 200 swelling kinetics, polybasic gels, 76
poly(DL-lactic acid) tablets, 26 swelling-controlled drug release, 195
poly(L-lactic acid) microspheres, 149
poly(L-lactic acid), 37 tableting indices, 26
poly(vinyl alcohol) beads, composite, 10 taurocholate uptake, 1152
polyacrylic nanoparticles, 1534 teniposide, 1556
polyalkylcyanoacrylate, nanoparticles, 441 terbutaline, ionized, 1035
polyalkylcyanoacrylates, 782 terbutaline, release rate, 220
polyanhydrides erosion, 1279 testosterone, metabolism, 1290
polybasic gels, swelling kinetics, 76 tetrachlorohydroquinone, 1053
polycarbophil, 70 theophylline, microdialysis, 1592
polyelectrolyte gel beads, 1268 theophylline-containing curdlan tablets, 414
polyethylene-imine, 37 therapeutic products, 1107
polymer-coated vesicles, 1137 thermal stability, salts of p-aminosalicylic acid, 1428
polymeric surfactants, 1177 thermodynamic activity, cholesterol, 792
polyvinyl alcohol, microparticles, 1330 thymidine analogues, metabolism, 326
powder mixing, 385 thyrotropin releasing hormone, 1113
powdered solution technology, 1351 tobramycin, implantable dosage form, 993
probenecid, 228 tomato lectin, bioadhesion, 547
progesterone, pharmacokinetics, 1502 tomato lectin, specific binding, 547
proliposomes, mixed micelles, 1556 topical drug delivery, 1422
propranolol hydrochloride, degradation, 312 topical vehicle formulation, 1546
propranolol, sustained delivery, 1507 torque, 1525
prostaglandin E,, NMR, 575 transdermal delivery, etorphine, 963
protein release, 37 transdermal drug delivery, 559, 1550
protein—peptide interactions, 990 transdermal drug delivery, ultrasound enhanced, 1043
pseudolatex, 200 transdermal penetration enhancers, 1168
pulmonary absorption, terbutaline, 220 transepithelial electrical resistance (TEER), 316
pulse polarography, 582 transport pathways, 1113
pyelonephritis, experimental, 1252 triamcinolone acetonide, 1359
1686 Subject Index
trichlormethiazide, 607 valpromide, pharmacokinetics, 1058
tricyclic antidepressants, 94 valpromide, stable analogues, 1058
trilostane, pharmacokinetics, 464 vasoactive drugs, 211
tryptophan fluorescence, 990
tumor necrosis factor, 33 X-ray fluorescence spectrometry, 5 iodouracil, 1410
X-ray photoelectron spectroscopy (XPS), 126
UNIFAC, 788 XE820, 1518
uranyl nitrate acute renal failure, 1599
urokase, 776 zidovudine distribution, brain, 332
zidovudine, 224
vaginal administration, insulin, 878 zidovudine, pharmacokinetics, 228
valproate, 1622 zileuton, degradation, 1465
valproic acid, enantiomers, 850 zinc binding, fibrolase, 870